Summit Therapeutics PLC Sponsored ADR Aktie News

Even in hindsight, it would have been difficult to predict Summit Therapeutics' (SMMT 2.88%) exceptional rise over the past three years. The company's shares have skyrocketed by more than 1,500% over this period.

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced the grant of inducement awards of options to purchase a collective total of up to 65,750 shares of common stock. Awards were made to eight new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Compan...

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be featured as part of the Presidential Sy...

While broad market performance has been robust, one striking aspect of this cycle has been the extraordinary gains in a handful of individual equities. Ten stocks in the large-cap Russell 1,000 have now advanced more than 1,000% since the start of this period. We take a look at each of these names to provide insight into the breadth of forces powering this bull market beyond the headline indices.

Summit Therapeutics Inc. (SMMT) is a U.S.-based biopharmaceutical company. It focuses on developing innovative medicines for cancer treatment.

LOS ANGELES, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Summit Therapeutics Inc. investors  ("Summit" or the "Company") (NASDAQ: SMMT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

The image featured for this article is © mezzotint / Shutterstock.com Latest Podcast Episode Eric Bleeker of The AI Investor Podcast catches up with 7investing CEO Simon Erickson 40 min Live News & Earnings • • 0 Updates Stock Market Live September 16: Good TikTok News Boosts Oracle, and the Whole S&P 500 (VOO) More Content Joey Frenette | Sep 16, 2025 Why I'd Buy GRNY Over the SPY Omor Ibne Eh...

LOS ANGELES, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The original press release, distributed Tuesday, September 9, 2025, incorrectly stated that a lawsuit was filed against Summit Therapeutics, in the headline and body of the release. The Portnoy Law Firm has commenced an investigation into Summit Therapeutics Inc. concerning alleged securities fraud. The corrected release follows.